Pharmaceutical Technology

DECEMBER 11, 2022

Due to the rarity of the disease, no FDA-approved therapy exists specifically for RT, and these patients are treated using regimens derived from the DLBCL treatment paradigm and other small-scale clinical trials. GlobalData’s consensus analyst forecast database projects peak sales for pirtobrutinib to reach $892 million by 2028, and $4.8

FDA 59

FDA Patients Safety Pharmaceutical 59

Pharmaceutical Technology

SEPTEMBER 15, 2022

According to GlobalData’s report, Paxlovid, the company’s small-molecule Covid-19 oral therapy, was shown to reduce Covid-19 infections by 32% in adults and is forecast to be the top-selling drug by total sales, generating $81bn between 2021 and 2028. AbbVie reported a 22.7% Bristol Myers Squibb (BMS) documented a 9.1%

Sales 108

Sales Competition Pharmaceutical Pharmaceutical research 108

Pharmaceutical Technology

SEPTEMBER 2, 2022

Previously, J&J’s/Legend Biotech’s Carvykti (cilta-cel) and Bristol Myers Squibb’s (BMS) Abecma (ide-cel), anti-BCMA chimeric antigen receptor (CAR) T-cells, were approved by both the EMA and the US Food and Drug Administration (FDA) for R/R MM. Does Blenrep have an efficacy advantage over Tecvayli?

Food and Drug Administration 59

Food and Drug Administration FDA Sales Physicians 59

pharmaphorum

AUGUST 4, 2022

Ten months after ChemoCentryx scored an unexpected FDA approval for autoimmune disease therapy Tavneos, Amgen has swooped in with a $3.7 billion bid to buy out the company.

Side effects 83

Side effects Pharma Sales Competition 83

European Pharmaceutical Review

AUGUST 21, 2023

Submission for US FDA regulatory approval, anticipated to be received by the end of 2023, further drove this progress, GlobalData noted. billion sales globally by 2029, this could offset Keytruda’s decline sales expected after its loss of exclusivity in 2028, GlobalData highlighted.

Biopharma 84

Biopharma Marketing Sales Medicine 84

Pharmaceutical Technology

NOVEMBER 8, 2022

Oyster Point Pharma introduced Tyrvaya, a nasal spray approved by the Food and Drug Administration (FDA) to treat dry eye disease, in November last year. These acquisitions could possibly add a minimum of $1bn in sales of Viatris by 2028. Famy Life Sciences has an ophthalmology portfolio that complements Viatris.

Food and Drug Administration 59

Food and Drug Administration Leads Pharma Food 59

pharmaphorum

AUGUST 2, 2022

Roche isn’t the only pharma company looking at subcutaneous checkpoint inhibitors, but the phase 3 readout and a plan to submit the data for approval with regulators including the FDA and EMA puts it among the leaders in the category. Results from a trial in first-line NSCLC are due in early 2023.

Marketing 99

Marketing Competition Patients FDA 99

Pharmaceutical Technology

AUGUST 16, 2022

Enhertu has already achieved regulatory approval as a second-line therapy for metastatic or recurrent HER2-positive breast cancer, as well as HER2-positive gastric or gastroesophageal junction adenocarcinoma, with annual sales for these indications alone expected to exceed $1.3bn by 2028.

Food and Drug Administration 59

Food and Drug Administration Sales Patients Food 59

pharmaphorum

OCTOBER 10, 2022

Keytruda is due to lose patent protection in around 2028, and the threat of generic competition to it and other top sellers like type 2 diabetes therapy Januvia (sitagliptin) gives it one of the steeper patent cliffs among to-tier pharma groups. The post Boost for Merck as Acceleron drug clears key phase 3 hurdle appeared first on.

Sales 52

Sales FDA Pharma Competition 52

Medico Reach

MARCH 24, 2023

Immunotherapy To combat the deadly disease, numerous pharmaceutical companies are actively pursuing FDA approval, which reflects its enormous market potential. billion by 2028. Nanotechnology By 2028, the Nanotechnology Medicines Delivery Market is expected to be $141.2 These may include FDA grants and commercial success.

Marketing 52

Marketing Medicine Healthcare Healthcare 52

Medico Reach

MARCH 24, 2023

Immunotherapy To combat the deadly disease, numerous pharmaceutical companies are actively pursuing FDA approval, which reflects its enormous market potential. billion by 2028. Nanotechnology By 2028, the Nanotechnology Medicines Delivery Market is expected to be $141.2 These may include FDA grants and commercial success.

Marketing 52

Marketing Medicine Healthcare Healthcare 52

Pharmaceutical Technology

JANUARY 19, 2023

However, it is possible to target CD33 in the clinic, as evidenced by the FDA approval of Pfizer’s anti-CD33 antibody-drug conjugate Mylotarg (gemtuzumab ozogamicin) in 2000. None of these products are in a registrational trial, and as such, GlobalData does not anticipate their entry into the AML market earlier than 2028.

Marketing 52

Marketing FDA Sales Management 52

pharmaphorum

AUGUST 8, 2022

billion in 2028 – a leap forward from the $195 million it made last year and $127 million in the first half of 2022. $PFE $GBT [link] pic.twitter.com/52AMCbvFHF. — Brad Loncar (@bradloncar) August 8, 2022. Oxbryta is the main asset in the deal, with Evaluate predicting sales could reach $1.5

Marketing 102

Marketing Sales Pharma FDA 102

Pharmaceutical Technology

MARCH 23, 2023

Among other late-stage trials, Padcev is being evaluated in combination with Keytruda (pembrolizumab) in the frontline setting, with the trial granted priority review by the FDA. GlobalData analysts forecast the total revenue from Seagen products to be around $36bn from 2023 to 2028, with a 29.3%

Engineering 59

Engineering Sales Patients Marketing 59

Pharmaceutical Technology

JULY 12, 2022

The success of chimeric antigen receptor T-cells (CAR-T) in blood cancers has led to the US Food and Drug Administration's (FDA) approval of six products with a pipeline of cell therapies that numbers in the thousands. The total market for cell therapies in oncology is projected to exceed $37bn worldwide by 2028.

Leads 52

Leads Food and Drug Administration Marketing Sales 52

Pharmaceutical Technology

OCTOBER 28, 2022

In June 2021, the FDA approved Pfizer’s Prevnar 20 for adult use, although a nod for paediatric use is pending. Merck, known outside of the US and Canada as MSD, is developing its portfolio of pneumococcal vaccines , and has secured an FDA approval for the paediatric use of its 15-serotype vaccine Vaxneuvance in June.

Training 64

Training Marketing Competition FDA 64

Pharmaceutical Technology

MARCH 22, 2023

The device received Breakthrough Device Designation from the US Food and Drug Administration (FDA) in December 2020 as no standard of care for the condition existed. Expected to receive FDA approval by February 2026, the app tracks usage and provides personalised schedules to help reduce use, increase compliance, and reduce pain levels.

Food and Drug Administration 52

Food and Drug Administration Healthcare Healthcare Medical 52

PM360

SEPTEMBER 21, 2023

In March, the FDA approved several new naloxone products using the pathway, including one from Amphastar, which will compete with other intranasal on the market. This increases to 15 Part D drugs in 2026, as well as 15 Part B and D drugs in 2028, and a full 20 Part B and D drugs in 2029.

Management 105

Management Manufacturing Sales Competition 105

Contrarian Sales Techniques

FEBRUARY 10, 2023

According to various market research reports, the global non-invasive medical devices market was valued at approximately USD 45 billion in 2020 and is expected to grow at a compound annual growth rate (CAGR) of over 6% from 2021 to 2028. This growth is driven by several factors, including: 1.

Healthcare 52

Healthcare Healthcare Manufacturing Medical 52

Vodori

APRIL 18, 2022

With a growth rate of 7 percent anticipated by 2028 , the life science industry is expanding, on average, faster than any other. And if, to meet a deadline, a team pushes a piece through without adequate review, it could mean a fine from the FDA. The pandemic has also thrust life sciences onto the global center stage.

Training 52

Training Distribution FDA Specialization 52

European Pharmaceutical Review

NOVEMBER 14, 2023

Europe’s pharmaceutical packaging market to value over $35bn by 2028 The post USP General Chapter <660>—Glass revised appeared first on European Pharmaceutical Review. The PD EC plans to publish another major revision to <660> to modernise the testing procedures in the chapter, USP stated.

Food and Drug Administration 99

Food and Drug Administration Manufacturing Distribution Food 99

Pharmaceutical Technology

MARCH 30, 2023

billion in 2028. Earlier in March, the FDA shared a draft guidance on how to run clinical trials for the accelerated approval of cancer drugs. Earlier in March, the FDA shared a draft guidance on how to run clinical trials for the accelerated approval of cancer drugs.

Food and Drug Administration 52

Food and Drug Administration FDA Sales Food 52

European Pharmaceutical Review

FEBRUARY 14, 2023

In August 2021, mRNA-1345 gained Fast Track designation from the US Food and Drug Administration (FDA) in adults over 60 years old. According to a recent market research report , a total of five marketed mRNA non-vaccine products will generate over $2 billion by 2028. billion during 2028, GlobalData forecasted in its report.

Food and Drug Administration 92

Food and Drug Administration Medicine Safety Consulting 92

Pharmaceutical Technology

MAY 19, 2023

Rituxan received its first FDA approval in 1997 for the treatment of B-cell non-Hodgkin’s lymphoma (B-NHL) and reached peak global sales of $7.5bn in 2014. Roche’s anti-CD20 monoclonal antibody Rituxan/MabThera (rituximab) is one of the most successful oncology drugs of all time.

Sales 59

Sales Competition Marketing Patients 59

Medico Reach

OCTOBER 17, 2022

million by 2028. Quite recently, the Food and Drug Administration (FDA) marked a historical moment when it approved Patient Specific Talus Spacer 3D-printed implants in 2021. Now, the demand for such equipment is on track to grow exponentially. Development Of New Biotech Coating In Orthopedic Medical Devices.

Medical 98

Medical Food and Drug Administration Healthcare Healthcare 98

pharmaphorum

OCTOBER 18, 2022

Akouos has a portfolio of experimental gene therapies led by AK-OTOF, which uses an adeno-associated virus (AAV) vector to a functional copy of the otoferlin (OTOF) gene and was recently approved for clinical testing by the FDA. per month if conditions are not met, until the end of 2028 when they will all expire.

Medicine 52

Medicine FDA Patients Pharma 52

pharmaphorum

SEPTEMBER 13, 2022

2001– FDA green lights revolutionary treatments. Just over a decade after it was developed by biochemist Nicholas Lyndon, Imatinib received US Food and Drug Administration (FDA) approval in 2001. Today, the bone marrow donor registry comprises more than 39,527,166 donors and 804,246 cord blood units. 2002 – Emergence of CAR-T therapy.

Food and Drug Administration 87

Food and Drug Administration Patients Engineering Physicians 87

Medico Reach

OCTOBER 17, 2022

million by 2028. Quite recently, the Food and Drug Administration (FDA) marked a historical moment when it approved Patient Specific Talus Spacer 3D-printed implants in 2021. Now, the demand for such equipment is on track to grow exponentially. Development Of New Biotech Coating In Orthopedic Medical Devices.

Medical 52

Medical Food and Drug Administration Healthcare Healthcare 52

Pharmaceutical Technology

AUGUST 24, 2022

CAGR between 2020 and 2028. The FDA and/or other regulatory agencies typically request validation reports to evaluate the assay performance for the intended purpose.2,3. Patients provide blood samples for clinical trial sponsors to develop and deliver these emerging immunotherapies.

Transportation 52

Transportation Patients Safety Marketing 52

Pharmaceutical Technology

JUNE 16, 2023

In 2021, as part of the same Keynote-811 trial, the US Food and Drug Administration (FDA) granted accelerated approval to Keytruda for treating locally advanced unresectable or metastatic HER2-positive gastric or GEJ adenocarcinoma, in combination with trastuzumab and chemotherapy containing fluoropyrimidin and platinum.

Food and Drug Administration 52

Food and Drug Administration FDA Prospecting Food 52

Pharmaceutical Technology

APRIL 20, 2023

The district court had previously blocked Sandoz and Zydus from producing, selling, offering to sell, or importing generic versions of Otezla until February 2028. Since the lawsuit began, the FDA has approved Bristol Myers Squibb’s (BMS) Sotyktu (deucravacitinib), another small molecule for psoriasis treatment.

Competition 52

Competition Marketing FDA Prospecting 52

World of DTC Marketing

APRIL 7, 2022

By 2028, these costs are expected to climb to $6.2 Food and Drug Administration (FDA). In the Netherlands, only 12 percent of women said they had forgone care for cost reasons. THREAT 3: RISING HEALTHCARE COSTS. A study reported that U.S. healthcare spending during 2019 was nearly $3.8 trillion, or $11,582 per person.

Healthcare 215

Healthcare Healthcare Food and Drug Administration Government 215